TET2 contributes to gluconeogenesis and pathology of type 2 diabetes

  1. Tongji Hospital, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China
  2. MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
  3. Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
  4. Cellular and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University, Zhoushan, China
  5. UConn Center on Aging, UConn Health, Farmington, USA

Peer review process

Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a provisional response from the authors.

Read more about eLife’s peer review process.

Editors

  • Reviewing Editor
    Marcelo Mori
    State University of Campinas, Campinas, Brazil
  • Senior Editor
    David James
    University of Sydney, Sydney, Australia

Reviewer #1 (Public review):

Summary:

Zhang et al. describe a delicate relationship between Tet2 and FBP1 in the regulation of hepatic gluconeogenesis.

Strengths:

The studies are very mechanistic, indicating that this interaction occurs via demethylation of HNF4a. Phosphorylation of HNF4a at ser 313 induced by metformin also controls the interaction between Tet2 and FBP1.

Weaknesses:

The results are briefly described, and oftentimes, the necessary information is not provided to interpret the data. Similarly, the methods section is not well developed to inform the reader about how these experiments were performed. While the findings are interesting, the results section needs to be better developed to increase confidence in the interpretation of the results.

Reviewer #2 (Public review):

Summary:

This study reveals a novel role of TET2 in regulating gluconeogenesis. It shows that fasting and a high-fat diet increase TET2 expression in mice, and TET2 knockout reduces glucose production. The findings highlight that TET2 positively regulates FBP1, a key enzyme in gluconeogenesis, by interacting with HNF4α to demethylate the FBP1 promoter in response to glucagon. Additionally, metformin reduces FBP1 expression by preventing TET2-HNF4α interaction. This identifies an HNF4α-TET2-FBP1 axis as a potential target for T2D treatment.

Strengths:

The authors use several methods in vivo (PTT, GTT, and ITT in fasted and HFD mice; and KO mice) and in vitro (in HepG2 and primary hepatocytes) to support the existence of the HNF4alpha-TET-2-FBP-1 axis in the control of gluconeogenesis. These findings uncovered a previously unknown function of TET2 in gluconeogenesis.

Weaknesses:

Although the authors provide evidence of an HNF4α-TET2-FBP1 axis in the control of gluconeogenesis, which contributes to the therapeutic effect of metformin on T2D, its role in the pathogenesis of T2D is less clear. The mechanisms by which TET2 is up-regulated by glucagon should be more explored.

Author response:

eLife Assessment

Zhang et al. present important findings that reveal a new role for TET2 in controlling glucose production in the liver, showing that both fasting and a high-fat diet increase TET2 levels, while its absence reduces glucose production. TET2 works with HNF4α to activate the FBP1 gene upon glucagon stimulation, while metformin disrupts TET2-HNF4α interaction, lowering FBP1 levels and improving glucose homeostasis. While the results are solid, more details about the mechanisms and methods are needed to strengthen the study's conclusions

Thanks for the positive evaluation and constructive comments, which will significantly improve the quality of the manuscript. We will provide more details about the mechanisms and methods in the revised version.

Reviewer #1 (Public review):

Summary:

Zhang et al. describe a delicate relationship between Tet2 and FBP1 in the regulation of hepatic gluconeogenesis.

Strengths:

The studies are very mechanistic, indicating that this interaction occurs via demethylation of HNF4a. Phosphorylation of HNF4a at ser 313 induced by metformin also controls the interaction between Tet2 and FBP1.

Weaknesses:

The results are briefly described, and oftentimes, the necessary information is not provided to interpret the data. Similarly, the methods section is not well developed to inform the reader about how these experiments were performed. While the findings are interesting, the results section needs to be better developed to increase confidence in the interpretation of the results.

We thank the reviewer for the positive evaluation and constructive comments. There is a factual error in the paragraph of “Strengths”. The comment that “The studies are very mechanistic, indicating that this interaction occurs via demethylation of HNF4a. Phosphorylation of HNF4a at ser 313 induced by metformin also controls the interaction between Tet2 and FBP1.” should be revised as follows: “The studies are very mechanistic, indicating that this interaction occurs via demethylation of FBP1. Phosphorylation of HNF4a at ser 313 induced by metformin also controls the interaction between Tet2 and HNF4a.”

Following reviewer’s suggestions, we will provide all the necessary information in methods section to inform the reader about how these experiments were performed, and improve the description of the results in the revised revision.

Reviewer #2 (Public review):

Summary:

This study reveals a novel role of TET2 in regulating gluconeogenesis. It shows that fasting and a high-fat diet increase TET2 expression in mice, and TET2 knockout reduces glucose production. The findings highlight that TET2 positively regulates FBP1, a key enzyme in gluconeogenesis, by interacting with HNF4α to demethylate the FBP1 promoter in response to glucagon. Additionally, metformin reduces FBP1 expression by preventing TET2-HNF4α interaction. This identifies an HNF4α-TET2-FBP1 axis as a potential target for T2D treatment.

Strengths:

The authors use several methods in vivo (PTT, GTT, and ITT in fasted and HFD mice; and KO mice) and in vitro (in HepG2 and primary hepatocytes) to support the existence of the HNF4alpha-TET-2-FBP-1 axis in the control of gluconeogenesis. These findings uncovered a previously unknown function of TET2 in gluconeogenesis.

Weaknesses:

Although the authors provide evidence of an HNF4α-TET2-FBP1 axis in the control of gluconeogenesis, which contributes to the therapeutic effect of metformin on T2D, its role in the pathogenesis of T2D is less clear. The mechanisms by which TET2 is up-regulated by glucagon should be more explored.

We thank the reviewer for the supports and constructive comments, and agree with the reviewer that the current version mainly focused on the function of HNF4α-TET2-FBP1 axis in the control of gluconeogenesis. We will explore the pathogenesis of T2D and the mechanism how TET2 is up-regulated by glucagon in the revised revision.

Both reviewers made positive comments and we will address all the reviewers’ concerns either by new experiments or clarifications. We thank editors and reviewers for the constructive comments, which will significantly improve the quality of the manuscript.

  1. Howard Hughes Medical Institute
  2. Wellcome Trust
  3. Max-Planck-Gesellschaft
  4. Knut and Alice Wallenberg Foundation